Key Takeaways
- Shares of Alumis plummeted approximately 56% following the announcement that its Phase 2b LUMUS study of envudeucitinib did not achieve primary or secondary goals in lupus patients.
- The study included 408 participants but failed to reach its main goal of measuring disease activity improvement at the 48-week mark.
- A predetermined subset of patients with high interferon gene signatures demonstrated significant improvement, though this group was surprisingly underrepresented in the study.
- The biotech firm continues to pursue approval for envudeucitinib in plaque psoriasis, with an NDA submission planned for the fourth quarter of 2026.
- Management plans to discuss a Phase 3 trial design with regulatory authorities targeting the IFNGS-high lupus patient segment.
Shares of Alumis experienced a devastating collapse of approximately 56% during Tuesday’s trading session after the biotechnology company disclosed that its Phase 2b LUMUS clinical study of envudeucitinib failed to demonstrate efficacy in individuals suffering from moderate-to-severe systemic lupus erythematosus (SLE).
The equity declined as much as 57.86% intraday. Such a severe single-session decline represents a devastating blow for any biotechnology company.
The clinical study recruited 408 participants and evaluated disease activity utilizing the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at the 48-week timepoint. This served as the study’s primary efficacy measure, which was not achieved.
Additional secondary efficacy measures across the entire patient population also failed to reach statistical significance.
However, the company highlighted one potentially encouraging finding. A predetermined patient subset characterized by elevated interferon gene signatures, designated as IFNGS-high, demonstrated robust clinical improvement on both the primary efficacy measure and important secondary outcomes.
Patients classified as IFNGS-high represent the majority of individuals with moderate-to-severe SLE in clinical practice. Unfortunately, this patient population was unexpectedly underrepresented in the trial enrollment, which negatively impacted the overall study results.
According to Alumis, envudeucitinib demonstrated a favorable safety profile across the study duration. No unexpected safety concerns emerged during the trial.
Pharmacodynamic analyses additionally validated substantial dose-dependent modulation of interferon pathway activity, with the maximum dose of 40mg administered twice daily demonstrating the greatest pathway suppression.
Alumis’ Future Strategy
The biotechnology firm indicated it will initiate discussions with regulatory agencies regarding the design of a Phase 3 clinical program specifically targeting the IFNGS-high patient segment.
Alumis emphasized that no targeted oral treatment options currently exist for SLE, which the company believes justifies continued investment in this therapeutic area.
Development efforts in psoriasis continue uninterrupted. Alumis maintains its timeline to file a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis during the fourth quarter of 2026.
This regulatory submission builds upon encouraging results from the company’s Phase 3 ONWARD clinical program in plaque psoriasis.
Understanding Alumis’ Broader Context
Envudeucitinib functions as an oral allosteric inhibitor targeting tyrosine kinase 2 (TYK2). The compound modulates immune signaling pathways mediated by IL-23, IL-17, and Type I interferon.
The therapeutic mechanism remains consistent whether treating lupus or psoriasis, which explains why the IFNGS-high subset findings maintain relevance for investors and industry observers monitoring the development pipeline.
Prior to Tuesday’s selloff, the company commanded a market capitalization of approximately $2.99 billion. Year-to-date price appreciation had exceeded 123% before the clinical data announcement.
Typical daily trading volume averaged roughly 1.29 million shares before the trial results were disclosed.
Technical analysis indicators had assigned a Hold rating to the stock before the announcement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
